Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 94.8%

Neg 94.8% Neu 0% Pos 0%

Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $52 to $48.